RIPK1 and Parkinson disease: Studies have demonstrated that RIP1, RIP3 and pMLKL expression increased in brain tissue of PD patients (Hu et al., 2019; Oñate et al., 2020), and necroptosis pathway was activated in 6-hydroxydopamine (6-OHDA)-treated mice and midbrain primary neurons.